CervoMed Inc. Common Stock (CRVO)

FairStock Score: 28/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for a business I can understand, with durable competitive advantages, honest accounting, and a margin of safety in price. CervoMed is a 15-employee clinical-stage biotech developing neflamapimod for age-related neurologic disorders. That is a worthy scientific pursuit, but it is not yet a business in the Graham sense: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was not available and net loss was $6.6 million, or $0.64 per diluted share. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue was also not available and net loss was $8.0 million, or $0.86 per diluted share. For FY2025, ended 2025-12-31, revenue was $4.0 million and net loss was $27.0 million, or $2.98 per diluted share. That is worse than FY2024, when revenue was $9.7 million and net loss was $16.3 million; FY2023 revenue was $7.1 million and net loss was $2.2 million. Losses are widening while revenue has fallen. The trailing free cash flow was -$28.0 million, a -81.5% yield against the $34.3 million market cap as of the 2026-10-13 close. That means the company is consuming cash at a rate close to its entire market value each year. At the 2026-10-13 close of $2.27, FairStock calculations show a P/E of -0.71 and P/B of 1.34; ROE is -107.62%, ROCE is -60.80%, Piotroski is 1/9, Altman Z is 1.81, and the FairStock Score is 28/100. The Lynch category is none because it lost money in each of the last four years. There is no durable moat I can identify—only a binary drug candidate and intellectual property that must still prove itself. At $2.27, near the low end of the $2.13-$10.00 52-week range, the price may look low, but without earnings or reliable cash flow there is no calculable margin of safety. This is speculation, not value investing.

In plain English: CervoMed is a tiny drug developer trying to create a treatment for age-related brain and nerve diseases. It has no approved product and no recent revenue, and it is losing millions of dollars while spending cash on research. The share price is low, but because there are no profits or steady sales, it is hard to call it cheap on the numbers; much depends on whether the drug works.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer